Real‐world treatment patterns among patients diagnosed with hormone receptor‐positive metastatic breast cancer in the USA
There is a temporal increase in first-line treatment with AIs + CDK4/6 inhibitors and pertuzumab in dnMBC in the USA but with significant disparities by race and ethnicity.
Authors
- Antoinette M. Stroup (ORCID: https://orcid.org/0000-0003-3341-4018)
- Elisa V. Bandera (ORCID: https://orcid.org/0000-0002-8789-2755)
- Coral Omene (ORCID: https://orcid.org/0000-0001-7824-1478)
- Farzin Khosrow‐Khavar (ORCID: https://orcid.org/0000-0003-3636-8918)
- Kexin Zhu (ORCID: https://orcid.org/0000-0001-7173-6881)
Institutions
- Rutgers, The State University of New Jersey (US)
- Johnson University (US)
- Environmental and Occupational Health Sciences Institute (US)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-07-30
- DOI
- https://doi.org/10.1002/bcp.70183
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Heart Association
- California Department of Public Health
- University of Southern California
- Centers for Disease Control and Prevention
- University of California, San Francisco
- National Cancer Institute